Randomized Evaluation of Radotinib Versus Imatinib in Phase III Study for Efficacy With Chinese P… (NCT03722420) | Clinical Trial Compass
Active — Not RecruitingPhase 3
Randomized Evaluation of Radotinib Versus Imatinib in Phase III Study for Efficacy With Chinese Patients (RERISE China)
China238 participantsStarted 2018-12-28
Plain-language summary
This is a Phase III, multi-center, open-label, parallel, 2-arm, randomized study to evaluate the efficacy and safety of radotinib 300 mg Bis In Die(BID) versus imatinib 400 mg Quaque Die(QD).
This study will be conducted in Chinese patients with newly diagnosed Ph+ Chronic Myelogenous Leukemia(CML)-Chronic Phase(CP) who are previously untreated for Chronic Myelogenous Leukemia(CML).
Who can participate
Age range18 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
✓. China who are 18 years of age or older.
✓. Eastern cooperative oncology group (ECOG) score 0, 1, or 2.
✓. Patients with confirmed diagnosis of CML-CP within last 6 months.
✓. Patients with cytogenetically confirmed Ph+ CML in chronic phase
✓. Patients with typical BCR-ABL1 transcript type such as b2a2 and b3a2.
✓. Patients with adequate organ function.
✓. Women of childbearing potential should have negative serum or urine pregnancy test within 14 days before study entry.
✓. Patients providing written informed consent before initiation of any study-related activities.
Exclusion criteria
✕. Patients with Philadelphia chromosome negative but BCR-ABL1 positive CML.
✕. Patients who had been treated with interferon or other targeted anti-cancer therapy which inhibits the growth of leukemic cells